Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05757102 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
A Phase 3 study of Asthma, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 292
- Enrollment target
- 20
- Study locations
NCT05757102 is a Phase 3 study of Asthma that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 292 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT05757102, a Phase 3 study of Asthma, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 292 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.
Conditions Studied
Interventions
- DRUG FF/UMEC/VI
- DEVICE ELLIPTA
- DRUG FF/VI
Study Locations (20)
California
- GSK Investigational Site - Bakersfield
- GSK Investigational Site - Huntington Beach
- GSK Investigational Site - Mission Viejo
- GSK Investigational Site - Rolling Hills Estates
- GSK Investigational Site - Walnut Creek
Florida
- GSK Investigational Site - Aventura
- GSK Investigational Site - Miami
- GSK Investigational Site - Miami
- GSK Investigational Site - Miami
Alabama
- GSK Investigational Site - Birmingham
- GSK Investigational Site - Mobile
Arizona
- GSK Investigational Site - Paradise Valley
Colorado
- GSK Investigational Site - Colorado Springs
Georgia
- GSK Investigational Site - Savannah
Illinois
- GSK Investigational Site - Normal
Kentucky
- GSK Investigational Site - Owensboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 2023-04-25 |
| Est. Completion | 2027-01-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05757102
The ClinicalTrials.gov registry entry for NCT05757102 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 292 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (81% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 3 interventions - of which FF/UMEC/VI is the first listed.
NCT05757102 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT05757102 about?
NCT05757102 is a clinical study titled "A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma". The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.
What is the current status of trial NCT05757102?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 292 participants. The study started on 2023-04-25. Estimated completion is 2027-01-15.
What conditions does trial NCT05757102 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT05757102?
The interventions under investigation include: FF/UMEC/VI (DRUG), ELLIPTA (DEVICE), FF/VI (DRUG).
Who is sponsoring clinical trial NCT05757102?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05757102 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
-
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.